Related references
Note: Only part of the references are listed.Molecular profiling for precision cancer therapies
Eoghan R. Malone et al.
GENOME MEDICINE (2020)
A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer
Sant P. Chawla et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Functional significance of U2AF1 S34F mutations in lung adenocarcinomas
Mohammad S. Esfahani et al.
NATURE COMMUNICATIONS (2019)
Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy
Ahmad Al-Shihabi et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists
Erlinda M. Gordon et al.
MOLECULAR AND CLINICAL ONCOLOGY (2018)
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
Jonas Cicenas et al.
CANCERS (2017)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
Magali Olivier et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma
Sant P. Chawla et al.
MOLECULAR THERAPY (2009)
Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (rexin-G) in patients with advanced pancreatic cancer
Evanthia Galanis et al.
MOLECULAR THERAPY (2008)
The p53 tumor suppressor participates in multiple cell cycle checkpoints
Luciana E. Giono et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Reduced hepatic tumor incidence in cyclin G1-deficient mice
MR Jensen et al.
HEPATOLOGY (2003)
Cyclin G1 associates with MDM2 and regulates accumulation and degradation of p53 protein
SH Kimura et al.
GENES TO CELLS (2002)
Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice
EM Gordon et al.
HUMAN GENE THERAPY (2001)
Share Paper
